Serum Cytokine Profile in Patients With Pancreatic Cancer Torres Perales, Carolina Perales Romero, Sonia Alejandre Pérez, María José Iglesias, José Palomino Morales, Rogelio Jesús Martín Hernández, Miguel Caba Pérez, Octavio Prados Salazar, José Carlos Aránega Jiménez, Antonia Delgado, Juan Ramón Irigoyen, Antonio Ortuño Guzmán, Francisco Manuel Rojas Ruiz, Ignacio Linares Gil, Ana María serum diagnosis biomarker serum predictive biomarker pancreatic cancer cytokines Objective: Pancreatic ductal adenocarcinoma is a deadly disease because of late diagnosis and chemoresistance. We aimed to find a panel of serum cytokines representing diagnostic and predictive biomarkers for pancreatic cancer. Methods: A cytokine antibody array was performed to simultaneously identify 507 cytokines in sera of patients with pancreatic cancer and healthy controls. The nonparametric Mann-Whitney U test was used to pairwise compare the controls, the pretreated patients, and the posttreated patients. Fold changes greater than or equal to 1.5 or less than or equal to 1/1.5 were considered significant. Receiver operating characteristic curves were used to assess the performance of the model. A leave-one-out cross-validation was used for estimating prediction error. Results: Comparing the sera of pretreated patients against the control samples, the cytokines fibroblast growth factor 10 (FGF-10/keratinocyte growth factor-2 (KGF-2), chemokine (C-X-C motif) ligand 11 interferon inducible T cell alpha chemokine (I-TAC)/chemokine [C-X-C motif] ligand 11 (CXCL11), oncostatin M (OSM), osteoactivin/glycoprotein nonmetastatic melanoma protein B, and stem cell factor (SCF) were found significantly overexpressed. Besides, the cytokines CD30 ligand/tumor necrosis factor superfamily, member 8 (TNFSF8), chordin-like 2, FGF-10/KGF-2, growth/differentiation factor 15, I-TAC/CXCL11, OSM, and SCF were differentially expressed in response to treatment. Conclusions : We propose a role for FGF-10/KGF-2, I-TAC/CXCL11, OSM, osteoactivin/glycoprotein nonmetastatic melanoma protein B, and SCF as novel diagnostic biomarkers. CD30 ligand/TNFSF8, chordin-like 2, FGF-10/KGF-2, growth/differentiation factor 15, I-TAC/CXCL11, OSM, and SCF might represent as predictive biomarkers for gemcitabine and erlotinib response of patients with pancreatic cancer. 2025-01-31T08:12:46Z 2025-01-31T08:12:46Z 2014-10 journal article Cite Torres, Carolina PhD*; Perales, Sonia PhD*; Alejandre, María José PhD*; Iglesias, José PhD*; Palomino, Rogelio J. PhD*; Martin, Miguel PhD†; Caba, Octavio PhD‡; Prados, José C. PhD, MD§; Aránega, Antonia PhD, MD§; Delgado, Juan R. MD∥; Irigoyen, Antonio PhD, MD∥; Ortuño, Francisco M. PhD¶; Rojas, Ignacio PhD¶; Linares, Ana PhD*. Serum Cytokine Profile in Patients With Pancreatic Cancer. Pancreas 43(7):p 1042-1049, October 2014. https://hdl.handle.net/10481/101458 10.1097/MPA.0000000000000155 eng 43;7 http://creativecommons.org/licenses/by-nc-nd/3.0/ embargoed access Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License Lippincott Williams & Wilkins